Glioblastoma Market Size
DelveInsight's 'Glioblastoma - Market Insights, Epidemiology and Market Forecast-2028' report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the market trends of Glioblastoma in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Glioblastoma from 2017 to 2028 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
Geography Covered
• The United States
• EU5 (Germany, France, Italy, Spain and the United Kingdom)
• Japan
Study Period: 2017-2028
Glioblastoma - Disease Understanding and Treatment Algorithm
Glioblastoma (GBM) is the most frequently occurring type of primary tumors of the central nervous system (CNS) mostly in adults, and its poor prognosis has not been significantly improved despite the fact that the innovative diagnostic strategies and new therapies have been developed. Somatic evolution promotes the progression of cancer in which the genome of the cancer cell is being deviated from that of the healthy cell due the accumulation of mutations. There is a remarkable development in GBM because it occurs via a complex network of various different molecular and genetic aberrations, which leads to significant changes in major signaling pathways. GBMs, as they extensively disperse throughout the parenchyma, making maximal surgical resection unattainable and having high level of vascularization, are lethal in nature.
GBM is often located in a region of the forebrain known as the cerebrum, which controls some of the most advanced process such as speech and emotions. While GBM is highly locally invasive (invading normal brain tissue), it rarely spreads to other organs beyond the brain. A highly aggressive, fast-growing cancer and treatment is often limited by the tumor location and the ability of a patient to tolerate surgery. Consequently, it is a particularly difficult cancer to treat.
The DelveInsight Glioblastoma market report gives the thorough understanding of the Glioblastoma by including details such as disease definition, classification, types, symptoms, pathophysiology, inheritance, molecular classification diagnostic trends. It also provides treatment algorithms and treatment guidelines for Glioblastoma in the US, Europe, and Japan.
Glioblastoma Epidemiology
The Glioblastoma epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [segmented by Total Incident Population of Glioblastoma, Total Diagnosed Incident Population of Glioblastoma, Gender specific Diagnosed Incidence of Glioblastoma, Type specific Diagnosed Incidence of Glioblastoma and Incident Population of Associated Comorbidities in Glioblastoma scenario of Glioblastoma in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2028.
According to DelveInsight, incident population of Glioblastoma associated with menopause in 7MM countries is expected to increase at a CAGR of 1.11% for the study period i.e. 2017-2028. As per the estimates, United States has the highest incident population of Glioblastoma. Among the European countries, UK had the highest incident population of Glioblastoma with 3,492 cases, followed by France which had incident population of 2,683 in 2017.
Glioblastoma Drug Chapters
This segment of the Glioblastoma report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
The current therapeutic landscape of Glioblastoma in the report provides the detailed chapters of upcoming therapies such as late-stage therapies including Marizomib (Celgene), VAL-083 (DelMar Pharmaceuticals), JP0001 (Johnpro Biotech), and many more with the mid-stage products like Enzastaurin Hydrochloride (Denovo Biopharma; Eli Lilly), ALECSAT (CytoVac) and others, which are expected to launch during the forecast period [2019-2028] have also been covered in the report.
Glioblastoma Market Outlook
The Glioblastoma market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the market size of Glioblastoma in the seven major markets is expected to reach around USD 2,306 million by 2028. The United States accounts for the highest market size of Glioblastoma in comparison to the EU5 (the United Kingdom, Germany, Italy, France, and Spain), and Japan. Expected Launch of potential therapies may increase market size in the coming years, assisted by an increase in diagnosed incident population of Glioblastoma Multiforme. Owing to the positive outcomes of the several products during the developmental stage by key players such as DelMar Pharmaceuticals, Abbvie, Diffusion Pharmaceuticals, Tocagen, Apogenix etc. has a potential to create a significant positive shift in the Glioblastoma market size. DelveInsight's analysts estimate that the market is expected to show positive growth post 2022, due to the increased patient incidence and to the expected launch of emerging therapies.
Glioblastoma Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Expected launch of therapies for Glioblastoma such as Celgene's Marizomib, DelMar's VAL-083, Green Cross Cell's Immuncell-LC and other targeted therapies in the forecast period [2019-2028] will also create a positive impact on the Glioblastoma market.
Glioblastoma Report Insights
• Patient Population
• Therapeutic Approaches
• Pipeline Analysis
• Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies
Glioblastoma Report Key Strengths
• 10 Years Forecast
• 7MM Coverage
• Epidemiology Segmentation
• Key Cross Competition
• Market Size by Therapies
• Drugs Uptake
Glioblastoma Report Assessment
• Pipeline Product Profiles
• Key Products and Key Players
• Market Drivers and Barriers
Key Benefits
• This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Glioblastoma market
• Organize sales and marketing efforts by identifying the best opportunities for Glioblastoma market
• To understand the future market competition in the Glioblastoma market.
